ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug ALX2004 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called ALX2004 in people with advanced lung, head and neck, colorectal, or esophageal cancers that have stopped responding to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated May 26, 2026 08:01 UTC
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will check for safety and side effect…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1, PHASE2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated May 26, 2026 07:59 UTC
-
New combo therapy aims to shrink tough esophageal tumors
Disease control Recruiting nowThis study tests whether giving chemotherapy and immunotherapy before radiation works better than the usual chemoradiation for people with advanced esophageal cancer that cannot be removed by surgery. About 92 adults with stage III–IVA esophageal squamous cell carcinoma will be r…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Zunyi Medical University • Aim: Disease control
Last updated May 26, 2026 07:58 UTC
-
New combo therapy aims to wipe out esophageal cancer before surgery
Disease control Recruiting nowThis study tests whether adding adalimumab to standard chemotherapy and radiation before surgery can help eliminate esophageal cancer more effectively. About 37 adults with resectable esophageal squamous cell carcinoma will receive this combination. The main goal is to see how ma…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated May 26, 2026 07:57 UTC
-
Promising combo may turn inoperable esophageal cancer into operable disease
Disease control Recruiting nowThis study tests whether adding the drug tislelizumab to standard chemoradiation can shrink advanced esophageal cancer enough to allow surgery. About 45 adults with unresectable cancer will receive the combination, then possibly undergo surgery. The main goal is to see how many p…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Ming-Yu Lien • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
New hope for elderly esophageal cancer patients unfit for chemotherapy
Disease control Recruiting nowThis study tests a drug called tislelizumab in people aged 70 and older with advanced esophageal cancer who cannot receive standard chemotherapy. The drug is given by IV and aims to help patients live longer and with better quality of life. Researchers will track how many patient…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Disease control
Last updated May 26, 2026 07:51 UTC
-
Could a boost of radiation improve outcomes for esophageal cancer patients?
Disease control Recruiting nowThis early-phase trial is testing whether giving an extra, higher dose of radiation using MRI-guided technology can improve outcomes for people with a type of esophageal cancer. About 30 participants will receive the standard chemoradiation plus one or two extra radiation boosts.…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New combo therapy may let some esophageal cancer patients keep their esophagus
Disease control Recruiting nowThis early-phase study is testing whether giving a combination of chemotherapy and immunotherapy before any surgery can shrink esophageal cancer enough to allow doctors to remove the tumor through a scope, preserving the esophagus. About 60 adults with a specific type of esophage…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New hope for tough esophageal cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called QLC5508 against standard chemotherapy for people with advanced esophageal cancer that has gotten worse after previous treatments. About 466 adults will be randomly assigned to receive either QLC5508 or a chemotherapy chosen by their doctor. The …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug cocktail shows promise for tough esophageal cancer
Disease control Recruiting nowThis study tests a new drug called KC1036 combined with standard immunotherapy and chemotherapy as a first treatment for people with advanced or recurrent esophageal cancer that cannot be removed by surgery. About 60 adults aged 18 to 75 who have not had prior treatment for this …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Beijing Konruns Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
Double immunotherapy attack shows promise against tough esophageal cancer
Disease control Recruiting nowThis study tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy can shrink tumors and slow disease in people with advanced esophageal cancer that has come back or spread. About 25 adults whose cancer cannot be removed by surger…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Shorter radiation may improve esophageal cancer treatment
Disease control Recruiting nowThis study compares two types of radiation therapy for people with advanced esophageal cancer that cannot be removed by surgery. After initial chemo-immunotherapy, participants receive either a shorter course of higher-dose radiation or a standard longer course. The goal is to se…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
Breakthrough blood test could spot six cancers at once
Diagnosis Recruiting nowThis study is developing a blood test that looks for tiny molecules called miRNAs to detect several types of digestive system cancers (like liver, pancreatic, and colon cancer) early. The goal is to create a simple, noninvasive screening tool that can be used for large population…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated May 26, 2026 07:57 UTC